Recently, our President and Managing Director, Jennifer Che, participated as a speaker at the HKSTP Market Discovery - BIO Connect event, hosted by HKSTP and InvestHK. This exclusive gathering brought together international biotech disruptors, offering them valuable insights into accessing the vast markets of Asia and beyond.

In her talk titled "Biotech Disruptors Benefit from HK IP," Jennifer highlighted the unique advantages Hong Kong offers from an intellectual property perspective. She discussed the rapidly developing IP ecosystem, including the homegrown original grant patent system and various tax and funding incentives that make the region an attractive hub for research and development. Additionally, she emphasized the expertise of local firms like Eagle IP, which are adept at navigating the complex IP challenges within the Greater Bay Area.

我们的过去活动

Recommended Insights

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

How the Chinese Patent Office Rejected a Plate-Making Method Based on Food Safety Law

2022年10月19日
Previously we published an article about CNIPA rejecting a patent application claiming a food that could also be used to treat or prevent diseases based on the food’s alleged non-compliance with Food Safety Law. China’s Food Safety Law includes a provision which states any use of a composition as a food must be strictly separated […]

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

2025年9月4日
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Top crossarrow-right